|
WO2008022349A2
(en)
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
AU2008282496B2
(en)
|
2007-07-27 |
2013-04-04 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-iduronidase activity in the CNS
|
|
JP2013507131A
(ja)
|
2009-10-09 |
2013-03-04 |
アーメイゲン・テクノロジーズ・インコーポレイテッド |
Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
|
|
WO2012148994A1
(en)
|
2011-04-25 |
2012-11-01 |
Usher Iii Initiative |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8609820B2
(en)
|
2011-10-28 |
2013-12-17 |
Neotope Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
|
KR101998818B1
(ko)
|
2011-11-03 |
2019-07-10 |
한민규 |
무선 통신 장치의 장치 식별 정보를 이용한 컨텐츠 표시 방법, 컨텐츠 제공 방법, 상기 컨텐츠 표시 방법을 수행하는 사용자 단말 및 상기 컨텐츠 제공 방법을 수행하는 컨텐츠 제공 시스템
|
|
US20140323581A1
(en)
*
|
2011-12-05 |
2014-10-30 |
The Trustees Of Columbia University In The City Of New York |
Transcriptome wiring analysis in parkinson's disease and uses thereof
|
|
NZ629296A
(en)
|
2012-01-27 |
2016-06-24 |
Prothena Biosciences Ltd |
Humanized antibodies that recognize alpha-synuclein
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013182652A1
(en)
*
|
2012-06-06 |
2013-12-12 |
Fondazione Telethon |
Allosteric chaperones and uses thereof
|
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
JP2016503405A
(ja)
|
2012-11-05 |
2016-02-04 |
ジェンザイム・コーポレーション |
タンパク質症を処置するための組成物および方法
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
WO2014143242A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
EP2970289A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
US20160136229A1
(en)
*
|
2013-06-18 |
2016-05-19 |
University Of North Carolina At Pembroke |
Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
MX2021012208A
(es)
|
2013-10-04 |
2023-01-19 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos y usos de los mismos.
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
DK3077397T3
(da)
|
2013-12-06 |
2019-12-16 |
Vertex Pharma |
2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
|
|
WO2015121339A1
(en)
|
2014-02-14 |
2015-08-20 |
RUHR-UNIVERSITäT BOCHUM |
Biosensor for conformation and secondary structure analysis
|
|
NZ724368A
(en)
|
2014-03-19 |
2023-07-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
JP6744856B2
(ja)
|
2014-04-08 |
2020-08-19 |
プロセナ・バイオサイエンシズ・リミテッド |
α−シヌクレインを認識する抗体を含む血液脳関門シャトル
|
|
PL3152212T3
(pl)
|
2014-06-05 |
2020-06-15 |
Vertex Pharmaceuticals Inc. |
Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
CN105330579B
(zh)
*
|
2014-08-08 |
2019-08-30 |
杭州雷索药业有限公司 |
依泽替米贝及其衍生物在治疗或预防癫痫中的应用
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
HRP20240644T1
(hr)
|
2014-11-06 |
2024-08-02 |
Bial-R&D Investments, S.A. |
Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
|
|
AU2015342883B2
(en)
|
2014-11-06 |
2020-07-02 |
Bial - R&D Investments, S.A. |
Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
|
|
WO2016073889A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
WO2016077706A1
(en)
|
2014-11-13 |
2016-05-19 |
Washington University |
Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
|
|
WO2016081365A1
(en)
*
|
2014-11-19 |
2016-05-26 |
Rush University Medical Center |
Compositions and methods for treating lysosomal disorders
|
|
TW201642855A
(zh)
*
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
|
US10016514B2
(en)
|
2015-05-15 |
2018-07-10 |
New Hope Research Foundation |
Polynucleotides, vectors and methods for insertion and expression of transgenes
|
|
ES2924433T3
(es)
|
2015-06-11 |
2022-10-06 |
Usher Iii Initiative Inc |
Métodos de tratamiento o prevención de una proteopatía
|
|
US10604747B2
(en)
*
|
2015-08-06 |
2020-03-31 |
Academia Sinica |
Engineered enzyme for enzyme replacement therapy
|
|
WO2017040971A1
(en)
*
|
2015-09-03 |
2017-03-09 |
Biomarin Pharmaceutical Inc. |
Methods of using inhibitors of pikfyve for the treatment of lysosomal storage disorders and neurodegenerative diseases
|
|
EP4585268A3
(en)
|
2015-09-14 |
2025-10-15 |
Twelve Therapeutics, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
HK1258570A1
(zh)
|
2015-09-30 |
2019-11-15 |
Vertex Pharmaceuticals Inc. |
使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
|
|
US20190018000A1
(en)
|
2016-01-12 |
2019-01-17 |
Cedars-Sinai Medical Center |
A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
|
|
CN105534977A
(zh)
*
|
2016-01-14 |
2016-05-04 |
山东大学 |
T型钙离子通道抑制剂nnc55-0396在制备抗神经退行性疾病药物中的应用
|
|
US11473061B2
(en)
|
2016-02-01 |
2022-10-18 |
Cedars-Sinai Medical Center |
Systems and methods for growth of intestinal cells in microfluidic devices
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
EP3433623A2
(en)
*
|
2016-03-25 |
2019-01-30 |
Genzyme Corporation |
Biomarkers of proteopathies and uses thereof
|
|
EP3440081A4
(en)
*
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
US11192892B2
(en)
*
|
2016-04-06 |
2021-12-07 |
Bial—R&D Investments, S.A. |
Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
|
|
CA3020305A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
EP3452455A4
(en)
|
2016-05-05 |
2019-11-13 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
|
|
SG11201809693SA
(en)
|
2016-05-05 |
2018-11-29 |
Lysosomal Therapeutics Inc |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3318277A1
(en)
*
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
|
|
EP3538095A4
(en)
*
|
2016-11-14 |
2020-06-17 |
Berg LLC |
Methods for treating parkinson's disease
|
|
ES2834484T3
(es)
|
2016-11-21 |
2021-06-17 |
Univ Ruhr Bochum |
Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
|
|
US11174242B2
(en)
|
2016-12-29 |
2021-11-16 |
Minoryx Therapeutics S.L. |
Heteroaryl compounds and their use
|
|
WO2018140647A1
(en)
|
2017-01-25 |
2018-08-02 |
Cedars-Sinai Medical Center |
In vitro induction of mammary-like differentiation from human pluripotent stem cells
|
|
US11767513B2
(en)
|
2017-03-14 |
2023-09-26 |
Cedars-Sinai Medical Center |
Neuromuscular junction
|
|
US11414648B2
(en)
|
2017-03-24 |
2022-08-16 |
Cedars-Sinai Medical Center |
Methods and compositions for production of fallopian tube epithelium
|
|
JP7204235B2
(ja)
*
|
2017-08-02 |
2023-01-16 |
ストレスマーク・バイオサイエンシーズ・インコーポレイテッド |
活性型α－シヌクレインに結合する抗体
|
|
EP4379376A3
(en)
*
|
2017-09-07 |
2024-07-17 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treatment of hereditary cystatin c amyloid angiopathy ( hccaa) and other neurodegenerative disorders associated with aberrant amyloid deposits
|
|
AU2018345303B2
(en)
|
2017-10-02 |
2025-09-18 |
Denali Therapeutics Inc. |
Fusion proteins comprising enzyme replacement therapy enzymes
|
|
BR112020003725A2
(pt)
|
2017-10-06 |
2020-11-03 |
Forma Therapeutics, Inc. |
inibição da peptidase 30 específica de ubiquitina
|
|
KR20250016468A
(ko)
*
|
2018-02-02 |
2025-02-03 |
엔지반트 테라퓨틱스 게엠베하 |
파버병을 치료하는 방법
|
|
EP4700387A2
(en)
|
2018-03-23 |
2026-02-25 |
Cedars-Sinai Medical Center |
Methods of use of islet cells
|
|
EP3775161A4
(en)
|
2018-04-06 |
2022-04-06 |
Cedars-Sinai Medical Center |
NEURODEGENERATIVE DISEASE MODELS DERIVED FROM HUMAN PLURIPOTENTIC STEM CELLS ON A MICROFLUIDIC CHIP
|
|
US11981918B2
(en)
|
2018-04-06 |
2024-05-14 |
Cedars-Sinai Medical Center |
Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
|
|
BR112020020836A2
(pt)
|
2018-04-13 |
2021-01-19 |
University Of Massachusetts |
Vetores de aav bicistrônicos codificando subunidades alfa e beta de hexosaminidase e usos dos mesmos
|
|
EP3787613B1
(en)
|
2018-04-30 |
2026-03-11 |
Cedars-Sinai Medical Center |
Pkc activation for use in treating early onset sporadic parkinson's disease
|
|
JP7449242B2
(ja)
|
2018-05-17 |
2024-03-13 |
フォーマ セラピューティクス，インコーポレイテッド |
ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
|
|
IL279219B2
(en)
*
|
2018-06-08 |
2024-08-01 |
Ac Immune Sa |
Novel compounds for diagnosis
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
US12448629B2
(en)
|
2018-10-05 |
2025-10-21 |
University Of Massachusetts |
rAAV vectors for the treatment of GM1 and GM2 gangliosidosis
|
|
LT3860989T
(lt)
|
2018-10-05 |
2023-06-12 |
Forma Therapeutics, Inc. |
Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
|
|
CA3121785A1
(en)
|
2018-12-05 |
2020-06-11 |
Washington University |
Methods of detecting, preventing, reversing, and treating neurological diseases
|
|
EP3908611A4
(en)
*
|
2019-01-08 |
2022-10-12 |
Armagen, Inc. |
Methods and compositions for increasing galactosidase beta-1 activity in the cns
|
|
AU2020218496B2
(en)
*
|
2019-02-04 |
2024-12-19 |
Genzyme Corporation |
Methods for treating symptoms and disorders associated with lysosomal storage diseases
|
|
CN114040762A
(zh)
|
2019-02-04 |
2022-02-11 |
建新公司 |
使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
|
|
CN113573708A
(zh)
*
|
2019-02-07 |
2021-10-29 |
阿尔萨泰克公司 |
艾莫西平多价衍生物
|
|
KR20210143848A
(ko)
*
|
2019-03-22 |
2021-11-29 |
러쉬 유니버시티 메디컬 센터 |
리소좀 축적 장애를 위한 비강 유전자 전달 및 경구 신남산, 올레아미드 또는 젬피브로질의 병용
|
|
US20220226357A1
(en)
*
|
2019-04-29 |
2022-07-21 |
Thomas Jefferson University |
Methods for treating neurodegenerative disorders
|
|
EP3986412A4
(en)
|
2019-06-21 |
2023-11-15 |
The Broad Institute, Inc. |
Agents for reversing toxic proteinopathies
|
|
JP2022538608A
(ja)
*
|
2019-06-28 |
2022-09-05 |
ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア |
アルツハイマー病の治療のための鼻腔内ダントロレン投与
|
|
EP4005638A4
(en)
*
|
2019-07-29 |
2023-07-05 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
CN110579457B
(zh)
*
|
2019-09-20 |
2021-11-02 |
郑州大学第一附属医院 |
波形蛋白特异响应性荧光探针及其制备方法和应用
|
|
AU2021209954A1
(en)
*
|
2020-01-23 |
2022-09-01 |
Retispec Inc. |
Systems and methods for disease diagnosis
|
|
TW202142236A
(zh)
|
2020-02-03 |
2021-11-16 |
美商健臻公司 |
用於治療與溶體儲積症相關的神經症狀之方法
|
|
WO2021197396A1
(zh)
*
|
2020-03-31 |
2021-10-07 |
挪贝肽医药科技(上海)有限公司 |
氘代氧化苯砷化合物及其应用
|
|
CN113720812A
(zh)
*
|
2020-05-26 |
2021-11-30 |
重庆福莱鲨生物技术有限公司 |
一种测定蛋白溶解度的方法
|
|
IL299695A
(en)
|
2020-07-09 |
2023-03-01 |
Usher Iii Initiative Inc |
Treatment of cancer, inflammatory diseases and autoimmune diseases
|
|
KR20230043024A
(ko)
|
2020-07-24 |
2023-03-30 |
젠자임 코포레이션 |
벤글루스타트를 포함하는 제약 조성물
|
|
KR20230128462A
(ko)
|
2020-11-19 |
2023-09-05 |
제브라 덴마크 에이/에스 |
아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
|
|
EP4294811A2
(en)
*
|
2021-02-20 |
2023-12-27 |
Biohaven Therapeutics Ltd. |
Small molecules that bind to tdp-43 for the treatment of als and related disorders
|
|
CN113332267A
(zh)
*
|
2021-03-31 |
2021-09-03 |
中山大学孙逸仙纪念医院 |
苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
|
|
WO2022255893A1
(en)
*
|
2021-06-02 |
2022-12-08 |
Qatar Foundation For Education, Science And Community Development |
Methods for diagnosing and differentiating synucleinopathies
|
|
CA3232577A1
(en)
*
|
2021-09-20 |
2023-03-23 |
Alexander SHTILBANS |
Combination therapy for neurodegenerative diseases
|
|
CN116392490A
(zh)
*
|
2021-12-27 |
2023-07-07 |
中国科学院广州生物医药与健康研究院 |
氟桂利嗪的用途以及控制细胞内线粒体数量的方法
|
|
CN119236096B
(zh)
*
|
2024-10-11 |
2026-03-06 |
苏州大学 |
Grp94蛋白作为递药靶点在帕金森病药物载体构建中的应用
|
|
CN120771139A
(zh)
*
|
2025-07-18 |
2025-10-14 |
昆明理工大学 |
维拉帕米在制备治疗Rett综合征药物中的应用
|